凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
华兰生物(002007)公告正文

华兰生物:2012年第三季度报告全文

公告日期 2012-10-27
股票简称:华兰生物 股票代码:002007
                                                                     华兰生物工程股份有限公司 2012 年第三季度报告全文
                                          2012 年第三季度报告一、重要提示
    本公司董事会、监事会及董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性负个别及连带责任。
    所有董事均已出席了审议本次季报的董事会会议。
    公司负责人安康、主管会计工作负责人王启平及会计机构负责人(会计主管人员) 桑莉声明:保证季度报告中财务报告的真实、完整。二、公司基本情况(一)主要会计数据及财务指标以前报告期财务报表是否发生了追溯调整□ 是 √ 否 □ 不适用
                                                                                               本报告期末比上年度期末增减
                                     2012.9.30                         2011.12.31
                                                                                                           (%)
    总资产(元)                               2,985,198,208.50               2,734,936,388.09                            9.15%归属于上市公司股东的所有
                                           2,532,618,397.33               2,367,066,428.36                            6.99%者权益(元)
    股本(股)                                  576,204,800.00                  576,204,800.00归属于上市公司股东的每股
                                                        4.4                             4.11                          7.06%净资产(元/股)
                               2012 年 7-9 月        比上年同期增减(%)           2012 年 1-9 月       比上年同期增减(%)
    营业总收入(元)                   235,866,861.21                    -12.19%          673,968,499.22                 -8.73%归属于上市公司股东的净利
                                    60,072,741.57                    -33.64%          234,696,544.97                -23.87%润(元)经营活动产生的现金流量净
                                     --                       --                      160,838,770.70                 25.09%额(元)每股经营活动产生的现金流
                                     --                       --                               0.2791                 25.1%量净额(元/股)
    基本每股收益(元/股)                       0.1042                   -33.63%                   0.4073               -23.87%
    稀释每股收益(元/股)                       0.1042                   -33.63%                   0.4073               -23.87%
    加权平均净资产收益率(%)                   2.34%                     -1.71%                   9.45%                 -4.16%扣除非经常性损益后的加权
                                            2.05%                        -2%                    8.8%                 -4.83%平均净资产收益率(%)扣除非经常性损益项目和金额√ 适用 □ 不适用
                                                        年初至报告期期末金
                        项目                                                                            说明
                                                            额(元)
    非流动资产处置损益                                                 -4,110,159.53越权审批或无正式批准文件的税收返还、减免
                                                                 华兰生物工程股份有限公司 2012 年第三季度报告全文计入当期损益的政府补助(与企业业务密切相关,按照
                                                               7,579,000.00国家统一标准定额或定量享受的政府补助除外)计入当期损益的对非金融企业收取的资金占用费企业取得子公司、联营企业及合营企业的投资成本小于取得投资时应享有被投资单位可辨认净资产公允价值产生的收益非货币性资产交换损益委托他人投资或管理资产的损益因不可抗力因素,如遭受自然灾害而计提的各项资产减值准备债务重组损益企业重组费用,如安置职工的支出、整合费用等交易价格显失公允的交易产生的超过公允价值部分的损益同一控制下企业合并产生的子公司期初至合并日的当期净损益与公司正常经营业务无关的或有事项产生的损益除同公司正常经营业务相关的有效套期保值业务外,持有交易性金融资产、交易性金融负债产生的公允价值变动损益,以及处置交易性金融资产、交易性金融负债和可供出售金融资产取得的投资收益单独进行减值测试的应收款项减值准备转回对外委托贷款取得的损益采用公允价值模式进行后续计量的投资性房地产公允价值变动产生的损益根据税收、会计等法律、法规的要求对当期损益进行一次性调整对当期损益的影响受托经营取得的托管费收入
    除上述各项之外的其他营业外收入和支出                          -1,691,514.57
    其他符合非经常性损益定义的损益项目                            19,302,413.80
    少数股东权益影响额                                            -2,340,774.73
    所得税影响额                                                  -2,573,356.34
    合计                                                          16,165,608.63                    --公司对“其他符合非经常性损益定义的损益项目”以及根据自身正常经营业务的性质和特点将非经常性损益项目界定为经常性损益的项目的说明
           项目                涉及金额(元)                                   说明
    投资收益                               19,302,413.80 理财产品收益(二)报告期末股东总数及前十名股东持股情况表
    报告期末股东总数(户)                                                                                         54,463
                                     前十名无限售条件流通股股东持股情况
                             期末持有无限售条件股份的                         股份种类及数量
           股东名称
                                       数量                           种类                          数量
    新乡市华兰生物技术有限公司                   102,723,822 人民币普通股                                      102,723,822新乡市金康生物科技开发有限
                                                87,961,115 人民币普通股                                     87,961,115公司
                                                                华兰生物工程股份有限公司 2012 年第三季度报告全文
    香港科康有限公司                               76,889,088 人民币普通股                               76,889,088
    新乡市世辰生物技术有限公司                     24,604,400 人民币普通股                               24,604,400中国银行-大成蓝筹稳健证券
                                               11,018,463 人民币普通股                               11,018,463投资基金中国工商银行-汇添富均衡增
                                                8,053,675 人民币普通股                                8,053,675长股票型证券投资基金中国人民财产保险股份有限公
                                                7,140,370 人民币普通股                                7,140,370司-传统-普通保险产品兴业银行股份有限公司-兴全
                                                6,369,507 人民币普通股                                6,369,507全球视野股票型证券投资基金新华人寿保险股份有限公司-
    分红-个人分红-018L-FH002                       5,168,874 人民币普通股                                5,168,874深中国银行-易方达深证 100 交
                                                5,005,071 人民币普通股                                5,005,071易型开放式指数证券投资基金
                              上述第一、二、三、四股东存在关联关系,属于一致行动人。未知其他股东之间是否存在关股东情况的说明
                              联关系,是否属于一致行动人。三、重要事项(一)公司主要会计报表项目、财务指标大幅度变动的情况及原因√ 适用 □ 不适用
    1.   报告期末,公司应收票据较上年期末减少14,018万元,下降78.16%,主要系解付到期承兑汇票所致。
    2.   报告期末,公司其他流动资产较上年期末增加47,778万元,增长256.57%,主要系理财产品增加所致。
    3.   报告期末,公司短期借款较上年期末增加10,000万元,主要系增加项目贷款所致。
    4.   报告期末,公司预收账款较上年期末减少1,154万元,下降49.94%,主要系预收款完成结算所致。
    5.   报告期末,公司应付职工薪酬较上年期末增加61万元,增长118.84%,主要系未支付的工会经费及住房
    公积金增加所致。
    6.   报告期,公司资产减值损失较上年同期减少190万元,同比下降38.64%,主要系本报告期计提的坏账准
    备减少所致。
    7.   报告期,公司投资收益较上年同期增加1,822万元,同比增长1682.30%,主要系本报告期理财产品增加
    所致。
    8.   报告期,公司营业外收入较上年同期增加743万元,同比增长1540.54%,主要系本报告期收到政府各种
    补助增加所致。
    9.   报告期,公司营业外支出较上年同期增加491万元,同比增长401.22%,主要系本报告期非流动性资产
    处置增加所致。(二)重大事项进展情况及其影响和解决方案的分析说明1、非标意见情况□ 适用 √ 不适用2、公司存在向控股股东或其关联方提供资金、违反规定程序对外提供担保的情况□ 适用 √ 不适用
                                                              华兰生物工程股份有限公司 2012 年第三季度报告全文3、日常经营重大合同的签署和履行情况□ 适用 √ 不适用4、其他□ 适用 √ 不适用(三)公司或持股 5%以上股东在报告期内或持续到报告期内的承诺事项□ 适用 √ 不适用(四)对 2012 年度经营业绩的预计2012 年度预计的经营业绩情况:归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形2012 年度归属于上市公司股东的净利润变动幅
                                                                    -20%    至                             0%度2012 年度归属于上市公司股东的净利润变动区
                                                                29,657.94   至                       37,071.93间(万元)
    2011 年度归属于上市公司股东的净利润(元)                                                       370,719,279.33
                                            1、受关停五家单采血浆站的影响,血液制品营业收入下滑;2、原料血浆业绩变动的原因说明
                                            价格上涨,致使成本上升。(五)其他需说明的重大事项1、证券投资情况□ 适用 √ 不适用2、衍生品投资情况□ 适用 √ 不适用3、报告期末衍生品投资的持仓情况□ 适用 √ 不适用4、报告期内接待调研、沟通、采访等活动登记表
                                                                                           谈论的主要内容及
    接待时间         接待地点          接待方式          接待对象类型       接待对象
                                                                                               提供的资料5、发行公司债券情况是否发行公司债券□ 是 √ 否
                                                              华兰生物工程股份有限公司 2012 年第三季度报告全文四、附录(一)财务报表是否需要合并报表:√ 是 □ 否 □ 不适用如无特殊说明,财务报告中的财务报表的单位为:人民币元1、合并资产负债表编制单位: 华兰生物工程股份有限公司
                                                                                                       单位: 元
                 项目                            期末余额                              期初余额流动资产:
    货币资金                                                653,766,697.98                        884,499,769.59
    结算备付金
    拆出资金
    交易性金融资产
    应收票据                                                 39,161,253.00                        179,337,850.33
    应收账款                                                204,183,151.14                        166,772,977.46
    预付款项                                                120,374,764.61                        107,159,671.91
    应收保费
    应收分保账款
    应收分保合同准备金
    应收利息
    应收股利
    其他应收款                                                2,580,547.17                          2,547,764.99
    买入返售金融资产
    存货                                                    392,065,470.51                        319,025,933.12
    一年内到期的非流动资产
    其他流动资产                                            664,000,000.00                        186,218,888.90
    流动资产合计                                            2,076,131,884.41                      1,845,562,856.30非流动资产:
    发放委托贷款及垫款
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资
    投资性房地产
    固定资产                                                777,449,586.97                        741,199,936.51
    在建工程                                                 31,097,147.92                         42,788,493.64
    工程物资
    固定资产清理
    生产性生物资产                                            1,944,107.08                          2,203,662.26
                                华兰生物工程股份有限公司 2012 年第三季度报告全文
    油气资产
    无形资产                   89,519,468.09                       91,541,604.20
    开发支出
    商誉
    长期待摊费用
    递延所得税资产              9,056,014.03                       11,639,835.18
    其他非流动资产
    非流动资产合计                909,066,324.09                      889,373,531.79
    资产总计                     2,985,198,208.50                   2,734,936,388.09流动负债:
    短期借款                  100,000,000.00
    向中央银行借款
    吸收存款及同业存放
    拆入资金
    交易性金融负债
    应付票据
    应付账款                   43,139,037.99                       36,176,087.81
    预收款项                   11,570,646.73                       23,112,666.03
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬                1,130,805.09                         516,736.29
    应交税费                   -15,225,547.33                     -16,304,857.14
    应付利息
    应付股利
    其他应付款                 80,041,381.64                      110,484,982.25
    应付分保账款
    保险合同准备金
    代理买卖证券款
    代理承销证券款
    一年内到期的非流动负债
    其他流动负债
    流动负债合计                  220,656,324.12                      153,985,615.24非流动负债:
    长期借款
    应付债券
    长期应付款
    专项应付款
    预计负债
    递延所得税负债
    其他非流动负债
    非流动负债合计                           0.00                               0.00
    负债合计                      220,656,324.12                      153,985,615.24所有者权益(或股东权益):
                                                              华兰生物工程股份有限公司 2012 年第三季度报告全文
    实收资本(或股本)                                      576,204,800.00                        576,204,800.00
    资本公积                                                291,337,232.03                        291,337,232.03
    减:库存股
    专项储备
    盈余公积                                                185,457,420.47                        185,457,420.47
    一般风险准备
    未分配利润                                          1,479,618,944.83                      1,314,066,975.86
    外币报表折算差额
    归属于母公司所有者权益合计                              2,532,618,397.33                      2,367,066,428.36
    少数股东权益                                            231,923,487.05                        213,884,344.49
    所有者权益(或股东权益)合计                            2,764,541,884.38                      2,580,950,772.85
    负债和所有者权益(或股东权益)总计                      2,985,198,208.50                      2,734,936,388.09
    法定代表人:安康                      主管会计工作负责人:王启平                        会计机构负责人:桑莉2、母公司资产负债表编制单位: 华兰生物工程股份有限公司
                                                                                                       单位: 元
                 项目                            期末余额                              期初余额流动资产:
    货币资金                                                569,166,352.28                        707,209,945.85
    交易性金融资产
    应收票据                                                 39,161,253.00                        104,571,336.61
    应收账款                                                 32,942,220.46                         60,987,970.08
    预付款项                                                114,134,238.18                        103,351,064.50
    应收利息
    应收股利
    其他应收款                                               57,503,051.24                          6,538,218.38
    存货                                                    139,303,087.24                        192,555,334.93
    一年内到期的非流动资产
    其他流动资产                                            514,000,000.00                         72,840,000.00
    流动资产合计                                            1,466,210,202.40                      1,248,053,870.35非流动资产:
    可供出售金融资产
    持有至到期投资
    长期应收款                                                5,379,060.00                          5,379,060.00
    长期股权投资                                            552,866,697.11                        552,866,697.11
    投资性房地产
    固定资产                                                189,938,788.51                        111,289,447.48
    在建工程                                                  8,821,709.62                         37,383,193.42
    工程物资
    固定资产清理
    生产性生物资产
                                  华兰生物工程股份有限公司 2012 年第三季度报告全文
    油气资产
    无形资产                     29,978,579.84                       31,154,424.08
    开发支出
    商誉
    长期待摊费用
    递延所得税资产                3,526,455.29                        3,459,581.41
    其他非流动资产
    非流动资产合计                  790,511,290.37                      741,532,403.50
    资产总计                       2,256,721,492.77                   1,989,586,273.85流动负债:
    短期借款                    100,000,000.00
    交易性金融负债
    应付票据
    应付账款                     24,651,850.39                       20,001,065.73
    预收款项                        409,860.00                         421,860.00
    应付职工薪酬                    760,007.72                          411,308.70
    应交税费                     10,086,800.99                       -7,235,750.35
    应付利息
    应付股利
    其他应付款                    6,151,248.89                         985,443.91
    一年内到期的非流动负债
    其他流动负债
    流动负债合计                    142,059,767.99                       14,583,927.99非流动负债:
    长期借款
    应付债券
    长期应付款
    专项应付款
    预计负债
    递延所得税负债
    其他非流动负债
    非流动负债合计                             0.00                               0.00
    负债合计                        142,059,767.99                       14,583,927.99所有者权益(或股东权益):
    实收资本(或股本)          576,204,800.00                      576,204,800.00
    资本公积                    291,337,232.03                      291,337,232.03
    减:库存股
    专项储备
    盈余公积                    185,457,420.47                      185,457,420.47
    一般风险准备
    未分配利润                 1,061,662,272.28                     922,002,893.36
    外币报表折算差额
    所有者权益(或股东权益)合计   2,114,661,724.78                   1,975,002,345.86
                                                                     华兰生物工程股份有限公司 2012 年第三季度报告全文
    负债和所有者权益(或股东权益)总计                             2,256,721,492.77                      1,989,586,273.85
    法定代表人:安康                             主管会计工作负责人:王启平                        会计机构负责人:桑莉3、合并本报告期利润表编制单位: 华兰生物工程股份有限公司
                                                                                                              单位: 元
                   项目                                 本期金额                              上期金额
    一、营业总收入                                                     235,866,861.21                        268,604,446.87
       其中:营业收入                                              235,866,861.21                        268,604,446.87
             利息收入
             已赚保费
             手续费及佣金收入
    二、营业总成本                                                     181,388,491.28                        159,085,173.66
       其中:营业成本                                              106,728,570.29                         74,687,006.72
             利息支出
             手续费及佣金支出
             退保金
             赔付支出净额
             提取保险合同准备金净额
             保单红利支出
             分保费用
             营业税金及附加                                          3,761,521.57                          4,234,061.45
             销售费用                                               38,881,152.96                         32,320,821.56
             管理费用                                               33,657,169.42                         51,649,534.33
             财务费用                                               -5,297,083.34                         -6,783,530.37
             资产减值损失                                            3,657,160.38                          2,977,279.97
      加    :公允价值变动收益(损失以“-”号填列)
             投资收益(损失以“-”号填
                                                                     7,583,037.33                           207,923.63列)
          其中:对联营企业和合营企业的投资收益
             汇兑收益(损失以“-”号填列)
    三、营业利润(亏损以“-”号填列)                                  62,061,407.26                        109,727,196.84
       加   :营业外收入                                             2,226,176.25                           166,554.37
       减   :营业外支出                                             1,068,688.45                           231,321.92
             其中:非流动资产处置损失                                 387,492.80
    四、利润总额(亏损总额以“-”号填列)                              63,218,895.06                        109,662,429.29
       减:所得税费用                                                3,903,736.57                         16,648,399.30
    五、净利润(净亏损以“-”号填列)                                  59,315,158.49                         93,014,029.99
       其中:被合并方在合并前实现的净
                                                                             0.00利润
       归属于母公司所有者的净利润                                   60,072,741.57                         90,519,691.43
                                                                  华兰生物工程股份有限公司 2012 年第三季度报告全文
    少数股东损益                                                  -757,583.08                          2,494,338.56
    六、每股收益:                                          --                                    --
    (一)基本每股收益                                                0.1042                                 0.157
    (二)稀释每股收益                                                0.1042                                 0.157七、其他综合收益
    八、综合收益总额                                                 59,315,158.49                         93,014,029.99
    归属于母公司所有者的综合收益总
                                                                 60,072,741.57                         90,519,691.43额
    归属于少数股东的综合收益总额                                  -757,583.08                          2,494,338.56本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0.00 元。
    法定代表人:安康                          主管会计工作负责人:王启平                        会计机构负责人:桑莉4、母公司本报告期利润表编制单位: 华兰生物工程股份有限公司
                                                                                                           单位: 元
                 项目                                本期金额                              上期金额
    一、营业收入                                                    148,031,712.91                        172,070,466.37
    减:营业成本                                                66,458,403.71                         54,013,586.26
         营业税金及附加                                           1,979,533.37                          2,211,336.66
         销售费用                                                  147,101.87                            180,445.03
         管理费用                                                10,669,509.38                         11,286,841.89
         财务费用                                                -3,677,602.04                         -2,499,351.83
         资产减值损失
    加:公允价值变动收益(损失以“-”号填列)
         投资收益(损失以“-”号填列)                           5,843,174.19
        其中:对联营企业和合营企业的投资收益
    二、营业利润(亏损以“-”号填列)                               78,297,940.81                        106,877,608.36
    加:营业外收入                                                  99,303.99                             84,061.55
    减:营业外支出                                                931,500.34                              66,800.00
         其中:非流动资产处置损失                                  387,342.80
    三、利润总额(亏损总额以“-”号填列)                           77,465,744.46                        106,894,869.91
    减:所得税费用                                               4,453,876.98                         16,034,230.49
    四、净利润(净亏损以“-”号填列)                               73,011,867.48                         90,860,639.42
    五、每股收益:                                          --                                    --
    (一)基本每股收益
    (二)稀释每股收益六、其他综合收益
    七、综合收益总额                                                 73,011,867.48                         90,860,639.42
    法定代表人:安康                          主管会计工作负责人:王启平                        会计机构负责人:桑莉
                                                          华兰生物工程股份有限公司 2012 年第三季度报告全文5、合并年初到报告期末利润表编制单位: 华兰生物工程股份有限公司
                                                                                                   单位: 元
                   项目                      本期金额                              上期金额
    一、营业总收入                                          673,968,499.22                        738,447,615.67
       其中:营业收入                                   673,968,499.22                        738,447,615.67
             利息收入
             已赚保费
             手续费及佣金收入
    二、营业总成本                                          384,036,436.09                        363,505,122.70
       其中:营业成本                                   239,957,214.04                        209,022,875.39
             利息支出
             手续费及佣金支出
             退保金
             赔付支出净额
             提取保险合同准备金净额
             保单红利支出
             分保费用
             营业税金及附加                              10,904,789.60                         12,732,422.49
             销售费用                                    53,021,788.26                         47,271,665.99
             管理费用                                    93,543,355.56                        103,213,655.72
             财务费用                                   -16,409,014.41                        -13,654,245.57
             资产减值损失                                 3,018,303.04                          4,918,748.68
      加    :公允价值变动收益(损失以“-”号填列)
             投资收益(损失以“-”号填
                                                         19,302,413.80                          1,083,008.31列)
          其中:对联营企业和合营企业的投资收益
             汇兑收益(损失以“-”号填列)
    三、营业利润(亏损以“-”号填列)                      309,234,476.93                        376,025,501.28
       加   :营业外收入                                  7,917,133.00                           482,593.35
       减   :营业外支出                                  6,139,807.10                          1,224,964.56
             其中:非流动资产处置损失                     4,363,278.49                             23804.05
    四、利润总额(亏损总额以“-”号填列)                  311,011,802.83                        375,283,130.07
       减:所得税费用                                    58,276,115.30                         59,076,236.25
    五、净利润(净亏损以“-”号填列)                      252,735,687.53                        316,206,893.82
       其中:被合并方在合并前实现的净
                                                                  0.00                                  0.00利润
       归属于母公司所有者的净利润                       234,696,544.97                        308,297,082.22
       少数股东损益                                      18,039,142.56                          7,909,811.60
    六、每股收益:                                  --                                    --
       (一)基本每股收益                                      0.4073                                 0.535
                                                                  华兰生物工程股份有限公司 2012 年第三季度报告全文
    (二)稀释每股收益                                                0.4073                                 0.535七、其他综合收益
    八、综合收益总额                                                252,735,687.53                        316,206,893.82
    归属于母公司所有者的综合收益总
                                                                234,696,544.97                        308,297,082.22额
    归属于少数股东的综合收益总额                                18,039,142.56                          7,909,811.60年初到报告期末发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0.00 元。
    法定代表人:安康                          主管会计工作负责人:王启平                        会计机构负责人:桑莉6、母公司年初到报告期末利润表编制单位: 华兰生物工程股份有限公司
                                                                                                           单位: 元
                 项目                                本期金额                              上期金额
    一、营业收入                                                    469,661,469.80                        583,547,322.84
    减:营业成本                                               199,547,307.36                        192,076,383.07
         营业税金及附加                                           6,365,673.73                          8,295,260.45
         销售费用                                                  365,985.52                            359,321.24
         管理费用                                                29,138,273.48                         31,978,732.47
         财务费用                                               -13,923,619.51                         -5,408,164.12
         资产减值损失                                              445,825.85                             -29,274.86
    加:公允价值变动收益(损失以“-”号填列)
         投资收益(损失以“-”号填列)                          10,789,745.83                        112,500,000.00
        其中:对联营企业和合营企业的投资收益
    二、营业利润(亏损以“-”号填列)                              258,511,769.20                        468,775,064.59
    加:营业外收入                                               1,507,391.58                           257,633.55
    减:营业外支出                                               5,842,489.24                           984,160.00
         其中:非流动资产处置损失                                 4,276,849.56
    三、利润总额(亏损总额以“-”号填列)                          254,176,671.54                        468,048,538.14
    减:所得税费用                                              45,372,716.62                         53,336,671.95
    四、净利润(净亏损以“-”号填列)                              208,803,954.92                        414,711,866.19
    五、每股收益:                                          --                                    --
    (一)基本每股收益
    (二)稀释每股收益六、其他综合收益
    七、综合收益总额                                                208,803,954.92                        414,711,866.19
    法定代表人:安康                          主管会计工作负责人:王启平                        会计机构负责人:桑莉7、合并年初到报告期末现金流量表编制单位: 华兰生物工程股份有限公司
                                                                                                           单位: 元
                                                  华兰生物工程股份有限公司 2012 年第三季度报告全文
               项目                  本期金额                              上期金额一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                855,789,785.72                        798,755,944.59
    客户存款和同业存放款项净增加额
    向中央银行借款净增加额
    向其他金融机构拆入资金净增加额
    收到原保险合同保费取得的现金
    收到再保险业务现金净额
    保户储金及投资款净增加额
    处置交易性金融资产净增加额
    收取利息、手续费及佣金的现金
    拆入资金净增加额
    回购业务资金净增加额
    收到的税费返还                                1,489,000.00
    收到其他与经营活动有关的现金                 32,492,583.38                         30,628,529.22
    经营活动现金流入小计                            889,771,369.10                        829,384,473.81
    购买商品、接受劳务支付的现金                261,755,151.07                        350,131,776.13
    客户贷款及垫款净增加额
    存放中央银行和同业款项净增加额
    支付原保险合同赔付款项的现金
    支付利息、手续费及佣金的现金
    支付保单红利的现金
    支付给职工以及为职工支付的现金               70,440,290.20                         60,629,263.26
    支付的各项税费                              150,779,926.50                        196,174,284.01
    支付其他与经营活动有关的现金                245,957,230.63                         93,874,477.66
    经营活动现金流出小计                            728,932,598.40                        700,809,801.06
    经营活动产生的现金流量净额                      160,838,770.70                        128,574,672.75二、投资活动产生的现金流量:
    收回投资收到的现金                      2,693,218,888.90
    取得投资收益所收到的现金                     19,302,413.80
    处置固定资产、无形资产和其他长
                                                    134,204.11                           147,865.77期资产收回的现金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金                                                         269,857.53
    投资活动现金流入小计                        2,712,655,506.81                             417,723.30
    购建固定资产、无形资产和其他长
                                                 83,203,568.42                         55,250,780.70期资产支付的现金
    投资支付的现金                          3,171,000,000.00
    质押贷款净增加额
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金
    投资活动现金流出小计                        3,254,203,568.42                           55,250,780.70
                                                                 华兰生物工程股份有限公司 2012 年第三季度报告全文
    投资活动产生的现金流量净额                                    -541,548,061.61                         -54,833,057.40三、筹资活动产生的现金流量:
       吸收投资收到的现金
    其中:子公司吸收少数股东投资收到的现金
       取得借款收到的现金                                     100,000,000.00                                    0.00
       发行债券收到的现金
       收到其他与筹资活动有关的现金
    筹资活动现金流入小计                                          100,000,000.00                                    0.00
       偿还债务支付的现金
       分配股利、利润或偿付利息支付的
                                                               66,877,909.33                         172,861,440.00现金
    其中:子公司支付给少数股东的股利、利润
       支付其他与筹资活动有关的现金
    筹资活动现金流出小计                                           66,877,909.33                         172,861,440.00
    筹资活动产生的现金流量净额                                     33,122,090.67                         -172,861,440.00四、汇率变动对现金及现金等价物的影
                                                                   -44,621.63                           -236,401.53响
    五、现金及现金等价物净增加额                                  -347,631,821.87                         -99,356,226.18
       加:期初现金及现金等价物余额                           881,398,519.85                     1,079,226,303.28
    六、期末现金及现金等价物余额                                  533,766,697.98                         979,870,077.10
    法定代表人:安康                        主管会计工作负责人:王启平                         会计机构负责人:桑莉8、母公司年初到报告期末现金流量表编制单位: 华兰生物工程股份有限公司
                                                                                                          单位: 元
                  项目                             本期金额                               上期金额一、经营活动产生的现金流量:
       销售商品、提供劳务收到的现金                           642,449,331.89                         649,932,893.77
       收到的税费返还                                             703,000.00
       收到其他与经营活动有关的现金                            20,555,003.68                          13,269,776.73
    经营活动现金流入小计                                          663,707,335.57                         663,202,670.50
       购买商品、接受劳务支付的现金                           165,545,523.53                         322,381,770.36
       支付给职工以及为职工支付的现金                          21,711,792.32                          15,869,935.16
       支付的各项税费                                          89,821,151.55                         132,698,392.89
       支付其他与经营活动有关的现金                           182,660,586.73                          17,373,475.52
    经营活动现金流出小计                                          459,739,054.13                         488,323,573.93
    经营活动产生的现金流量净额                                    203,968,281.44                         174,879,096.57二、投资活动产生的现金流量:
       收回投资收到的现金                                 2,018,840,000.00                           151,602,550.38
       取得投资收益所收到的现金                                10,789,745.83                         112,500,000.00
       处置固定资产、无形资产和其他长                            2,743,640.46                             40,000.00
                                                              华兰生物工程股份有限公司 2012 年第三季度报告全文期资产收回的现金净额
    处置子公司及其他营业单位收到的现金净额
       收到其他与投资活动有关的现金
    投资活动现金流入小计                                      2,032,373,386.29                      264,142,550.38
    购建固定资产、无形资产和其他长
                                                             64,362,732.57                       32,187,871.24期资产支付的现金
       投资支付的现金                                     2,460,000,000.00                      235,012,197.11
    取得子公司及其他营业单位支付的现金净额
       支付其他与投资活动有关的现金
    投资活动现金流出小计                                      2,524,362,732.57                      267,200,068.35
    投资活动产生的现金流量净额                                 -491,989,346.28                       -3,057,517.97三、筹资活动产生的现金流量:
       吸收投资收到的现金
       取得借款收到的现金                                   100,000,000.00                                0.00
       发行债券收到的现金
       收到其他与筹资活动有关的现金
    筹资活动现金流入小计                                        100,000,000.00                                0.00
       偿还债务支付的现金
       分配股利、利润或偿付利息支付的
                                                             66,877,909.33                      172,861,440.00现金
       支付其他与筹资活动有关的现金
    筹资活动现金流出小计                                         66,877,909.33                      172,861,440.00
    筹资活动产生的现金流量净额                                   33,122,090.67                     -172,861,440.00四、汇率变动对现金及现金等价物的影
                                                                -43,369.66                         -236,401.53响
    五、现金及现金等价物净增加额                               -254,942,343.83                       -1,276,262.93
       加:期初现金及现金等价物余额                         704,108,696.11                      535,335,040.54
    六、期末现金及现金等价物余额                                449,166,352.28                      534,058,777.61
    法定代表人:安康                        主管会计工作负责人:王启平                      会计机构负责人:桑莉(二)审计报告
    审计意见                    未经审计
                                                                                 华兰生物工程股份有限公司
                                                                                              董事长:安康
                                                                                         2012 年 10 月 27 日
数据加载中...
prevnext
手机查看股票